FibroGen Inc $ 40.74 -0.16 (-0.4%)
Volume:
141,582
Avg Vol (1m):
617,067
Market Cap $:
3.71 Bil
Enterprise Value $:
3.08 Bil
P/E (TTM):
0.00
P/B:
8.45
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 16.33 | ||
| Equity-to-Asset | 0.56 | ||
| Debt-to-Equity | 0.09 | ||
| Debt-to-EBITDA | -0.21 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 5.11 | ||
| Beneish M-Score | -2.57 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -196.42 | ||
| Net Margin % | -191.78 | ||
| ROE % | -47.34 | ||
| ROA % | -27.27 | ||
| ROC (Joel Greenblatt) % | -163.16 | ||
| 3-Year Revenue Growth Rate | 0.5 | ||
| 3-Year EBITDA Growth Rate | 2.9 | ||
| 3-Year EPS without NRI Growth Rate | 1.5 |
FGEN
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 8.45 | ||
| PS Ratio | 30.93 | ||
| Price-to-Free-Cash-Flow | 94.75 | ||
| Price-to-Operating-Cash-Flow | 86.87 | ||
| EV-to-EBIT | -13.63 | ||
| EV-to-EBITDA | -15.08 | ||
| EV-to-Revenue | 25.82 | ||
| Current Ratio | 6.23 | ||
| Quick Ratio | 6.13 | ||
| Days Inventory | 413.93 | ||
| Days Sales Outstanding | 80.32 | ||
| Days Payable | 385.14 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 8.45 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 79.88 | ||
| Earnings Yield (Greenblatt) % | -7.33 |